Efficacy and safety of risperidone oral solution in agitation associated with dementia in the elderly

Detalhes bibliográficos
Autor(a) principal: Laks, Jerson
Data de Publicação: 2001
Outros Autores: Engelhardt, Eliasz, Marinho, Valeska [UNIFESP], Rozenthal, Marcia, Souza, Fernando de Castro e, Bacaltchuk, Josué [UNIFESP], Stoppe Junior, Alberto, Ferreira, R.c.r., Bottino, Cassio, Scalco, Mônica
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UNIFESP
Texto Completo: http://dx.doi.org/10.1590/S0004-282X2001000600005
http://repositorio.unifesp.br/handle/11600/1289
Resumo: BACKGROUND: Behavioral and psychological symptoms in dementia (BPSD) contribute to caregiver burden and institutionalization of elderly. Neuroleptics are prescribed to control agitation. Side effects of typical neuroleptics are harmful, making atypical neuroleptics an indication. OBJECTIVES: To evaluate efficacy and tolerability of risperidone oral solution (ROS) given once daily to demented elderly outpatients with BPSD (agitation). METHOD: Patients (n=26), 76.35±8.63 years, Diagnostic and Statistical Manual of Mental Disorders 4th ed. (DSM-IV) criteria for dementia. RSO was given, starting dose of 0.25 mg and increments of 0.25 mg every week. Mini-Mental State Examination (MMSE) assessed cognitive status, Behavioral and Emotional Activities Manifested in Dementia (BEAM-D) and Clinical Global Impression (CGI) measured BPSD, Extrapiramidal Symptom Rating Scale (ESRS) evaluated extrapyramidal symptoms. Cardiovascular side effects were evaluated clinically. RESULTS: There was a 26% reduction in agitation and no cardiovascular side effects in the range from 1.0 to 1.25 mg. Side effects were more prevalent above 2.5 mg. CONCLUSION: Risperidone oral solution improved agitation with good tolerability from 0.5 to 1.25 mg. A single dose with increments of 0.25 mg may be more acceptable to patients and caregivers.
id UFSP_6d6bd8014ae012d186468301ed0c1613
oai_identifier_str oai:repositorio.unifesp.br/:11600/1289
network_acronym_str UFSP
network_name_str Repositório Institucional da UNIFESP
repository_id_str 3465
spelling Efficacy and safety of risperidone oral solution in agitation associated with dementia in the elderlyEficácia e segurança de risperidona solução oral na agitação associada a demência em idososrisperidonedementiaBPSDelderlyrisperidonademênciaBPSDidososBACKGROUND: Behavioral and psychological symptoms in dementia (BPSD) contribute to caregiver burden and institutionalization of elderly. Neuroleptics are prescribed to control agitation. Side effects of typical neuroleptics are harmful, making atypical neuroleptics an indication. OBJECTIVES: To evaluate efficacy and tolerability of risperidone oral solution (ROS) given once daily to demented elderly outpatients with BPSD (agitation). METHOD: Patients (n=26), 76.35±8.63 years, Diagnostic and Statistical Manual of Mental Disorders 4th ed. (DSM-IV) criteria for dementia. RSO was given, starting dose of 0.25 mg and increments of 0.25 mg every week. Mini-Mental State Examination (MMSE) assessed cognitive status, Behavioral and Emotional Activities Manifested in Dementia (BEAM-D) and Clinical Global Impression (CGI) measured BPSD, Extrapiramidal Symptom Rating Scale (ESRS) evaluated extrapyramidal symptoms. Cardiovascular side effects were evaluated clinically. RESULTS: There was a 26% reduction in agitation and no cardiovascular side effects in the range from 1.0 to 1.25 mg. Side effects were more prevalent above 2.5 mg. CONCLUSION: Risperidone oral solution improved agitation with good tolerability from 0.5 to 1.25 mg. A single dose with increments of 0.25 mg may be more acceptable to patients and caregivers.FUNDAMENTOS: Sintomas psicológicos e do comportamento nas demências (BPSD) contribuem para a sobrecarga dos cuidadores e institucionalização dos idosos. Neurolépticos são prescritos para agitação. Efeitos colaterais dos típicos são prejudiciais, sendo os atípicos indicáveis. OBJETIVO: Avaliar eficácia e tolerabilidade da risperidona solução oral (RSO), dose única diária, em idosos demenciados ambulatoriais com BPSD (agitação). MÉTODO: Pacientes (n=26), 76,35±8,63 anos, critérios do Manual Diagnóstico e Estatístico de Transtornos Mentais 4.ed. (DSM-IV) para demência. RSO administrada, com dose inicial de 0,25 mg e incrementos de 0,25 mg toda semana. Foram utilizados mini-mental (MEEM) para estado cognitivo, behavioral and emotional activities manifested in dementia (BEAM-D) e clinical and global impression (CGI) para BPSD, extrapyramidal symptom rating scale (ESRS) para sintomas extrapiramidais. Efeitos colaterais cardiovasculares foram avaliados clinicamente. RESULTADOS: Houve redução de 26% na agitação, sem efeitos colaterais cardiovasculares, numa faixa de 1,0 a 1,25 mg. Efeitos colaterais foram mais prevalentes acima de 2,5 mg. CONCLUSÃO: Risperidona melhorou agitação com boa tolerabilidade entre 0,5 e 1,25 mg. Dose única diária e aumentos de 0,25 mg podem ser mais aceitáveis para pacientes e cuidadores.Federal University of Rio de Janeiro Institute of Psychiatry Psychogeriatric UnitUniversidade Federal de São Paulo (UNIFESP), Escola Paulista de Medicina (EPM)University of São Paulo Hospital das Clínicas Institute of PsychiatryUNIFESP, EPMSciELOAcademia Brasileira de Neurologia - ABNEUROFederal University of Rio de Janeiro Institute of Psychiatry Psychogeriatric UnitUniversidade Federal de São Paulo (UNIFESP)University of São Paulo Hospital das Clínicas Institute of PsychiatryLaks, JersonEngelhardt, EliaszMarinho, Valeska [UNIFESP]Rozenthal, MarciaSouza, Fernando de Castro eBacaltchuk, Josué [UNIFESP]Stoppe Junior, AlbertoFerreira, R.c.r.Bottino, CassioScalco, Mônica2015-06-14T13:29:33Z2015-06-14T13:29:33Z2001-12-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion859-864application/pdfhttp://dx.doi.org/10.1590/S0004-282X2001000600005Arquivos de Neuro-Psiquiatria. Academia Brasileira de Neurologia - ABNEURO, v. 59, n. 4, p. 859-864, 2001.10.1590/S0004-282X2001000600005S0004-282X2001000600005.pdf0004-282XS0004-282X2001000600005http://repositorio.unifesp.br/handle/11600/1289engArquivos de Neuro-Psiquiatriainfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESP2024-07-27T17:02:43Zoai:repositorio.unifesp.br/:11600/1289Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestbiblioteca.csp@unifesp.bropendoar:34652024-07-27T17:02:43Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false
dc.title.none.fl_str_mv Efficacy and safety of risperidone oral solution in agitation associated with dementia in the elderly
Eficácia e segurança de risperidona solução oral na agitação associada a demência em idosos
title Efficacy and safety of risperidone oral solution in agitation associated with dementia in the elderly
spellingShingle Efficacy and safety of risperidone oral solution in agitation associated with dementia in the elderly
Laks, Jerson
risperidone
dementia
BPSD
elderly
risperidona
demência
BPSD
idosos
title_short Efficacy and safety of risperidone oral solution in agitation associated with dementia in the elderly
title_full Efficacy and safety of risperidone oral solution in agitation associated with dementia in the elderly
title_fullStr Efficacy and safety of risperidone oral solution in agitation associated with dementia in the elderly
title_full_unstemmed Efficacy and safety of risperidone oral solution in agitation associated with dementia in the elderly
title_sort Efficacy and safety of risperidone oral solution in agitation associated with dementia in the elderly
author Laks, Jerson
author_facet Laks, Jerson
Engelhardt, Eliasz
Marinho, Valeska [UNIFESP]
Rozenthal, Marcia
Souza, Fernando de Castro e
Bacaltchuk, Josué [UNIFESP]
Stoppe Junior, Alberto
Ferreira, R.c.r.
Bottino, Cassio
Scalco, Mônica
author_role author
author2 Engelhardt, Eliasz
Marinho, Valeska [UNIFESP]
Rozenthal, Marcia
Souza, Fernando de Castro e
Bacaltchuk, Josué [UNIFESP]
Stoppe Junior, Alberto
Ferreira, R.c.r.
Bottino, Cassio
Scalco, Mônica
author2_role author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Federal University of Rio de Janeiro Institute of Psychiatry Psychogeriatric Unit
Universidade Federal de São Paulo (UNIFESP)
University of São Paulo Hospital das Clínicas Institute of Psychiatry
dc.contributor.author.fl_str_mv Laks, Jerson
Engelhardt, Eliasz
Marinho, Valeska [UNIFESP]
Rozenthal, Marcia
Souza, Fernando de Castro e
Bacaltchuk, Josué [UNIFESP]
Stoppe Junior, Alberto
Ferreira, R.c.r.
Bottino, Cassio
Scalco, Mônica
dc.subject.por.fl_str_mv risperidone
dementia
BPSD
elderly
risperidona
demência
BPSD
idosos
topic risperidone
dementia
BPSD
elderly
risperidona
demência
BPSD
idosos
description BACKGROUND: Behavioral and psychological symptoms in dementia (BPSD) contribute to caregiver burden and institutionalization of elderly. Neuroleptics are prescribed to control agitation. Side effects of typical neuroleptics are harmful, making atypical neuroleptics an indication. OBJECTIVES: To evaluate efficacy and tolerability of risperidone oral solution (ROS) given once daily to demented elderly outpatients with BPSD (agitation). METHOD: Patients (n=26), 76.35±8.63 years, Diagnostic and Statistical Manual of Mental Disorders 4th ed. (DSM-IV) criteria for dementia. RSO was given, starting dose of 0.25 mg and increments of 0.25 mg every week. Mini-Mental State Examination (MMSE) assessed cognitive status, Behavioral and Emotional Activities Manifested in Dementia (BEAM-D) and Clinical Global Impression (CGI) measured BPSD, Extrapiramidal Symptom Rating Scale (ESRS) evaluated extrapyramidal symptoms. Cardiovascular side effects were evaluated clinically. RESULTS: There was a 26% reduction in agitation and no cardiovascular side effects in the range from 1.0 to 1.25 mg. Side effects were more prevalent above 2.5 mg. CONCLUSION: Risperidone oral solution improved agitation with good tolerability from 0.5 to 1.25 mg. A single dose with increments of 0.25 mg may be more acceptable to patients and caregivers.
publishDate 2001
dc.date.none.fl_str_mv 2001-12-01
2015-06-14T13:29:33Z
2015-06-14T13:29:33Z
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://dx.doi.org/10.1590/S0004-282X2001000600005
Arquivos de Neuro-Psiquiatria. Academia Brasileira de Neurologia - ABNEURO, v. 59, n. 4, p. 859-864, 2001.
10.1590/S0004-282X2001000600005
S0004-282X2001000600005.pdf
0004-282X
S0004-282X2001000600005
http://repositorio.unifesp.br/handle/11600/1289
url http://dx.doi.org/10.1590/S0004-282X2001000600005
http://repositorio.unifesp.br/handle/11600/1289
identifier_str_mv Arquivos de Neuro-Psiquiatria. Academia Brasileira de Neurologia - ABNEURO, v. 59, n. 4, p. 859-864, 2001.
10.1590/S0004-282X2001000600005
S0004-282X2001000600005.pdf
0004-282X
S0004-282X2001000600005
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Arquivos de Neuro-Psiquiatria
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 859-864
application/pdf
dc.publisher.none.fl_str_mv Academia Brasileira de Neurologia - ABNEURO
publisher.none.fl_str_mv Academia Brasileira de Neurologia - ABNEURO
dc.source.none.fl_str_mv reponame:Repositório Institucional da UNIFESP
instname:Universidade Federal de São Paulo (UNIFESP)
instacron:UNIFESP
instname_str Universidade Federal de São Paulo (UNIFESP)
instacron_str UNIFESP
institution UNIFESP
reponame_str Repositório Institucional da UNIFESP
collection Repositório Institucional da UNIFESP
repository.name.fl_str_mv Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)
repository.mail.fl_str_mv biblioteca.csp@unifesp.br
_version_ 1814268414259101696

Registros relacionados